Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAF(V600E) Colorectal Cancer

PURPOSE: BRAF(V600E) mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Whereas selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Coffee, Erin M., Faber, Anthony C., Roper, Jatin, Sinnamon, Mark J., Goel, Gautam, Keung, Lily, Wang, Wei Vivian, Vecchione, Loredana, de Vriendt, Veerle, Weinstein, Barbara J., Bronson, Roderick T., Tejpar, Sabine, Xavier, Ramnik J., Engelman, Jeffrey A., Martin, Eric S., Hung, Kenneth E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815598/
https://ncbi.nlm.nih.gov/pubmed/23549875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2556
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge